11
Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Embed Size (px)

Citation preview

Page 1: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Palivizumab: a centralised clinic

Laura Marshall

RCN Conference

13th March 2008

Page 2: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Pavilizumab

Initially marketed in the late 1990’s to prevent the incidence of RSV+ in under two’s.

Due to lack of evidence and cost the JCVI made a tightened ‘at risk’ criteria for prescribing.

Therefore by utilising these guideline a local protocol was implemented.

Page 3: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Local criteria

Children under one year of age with chronic lung disease, receiving home oxygen therapy or prolonged oxygen use to a corrected gestational age of 36 weeks.

Infants less than six months of age with a haemodynamically

significant left to right shunt.  Infants were selected at the discretion of the paediatric cardiologist

Children under two years of age with severe congenital immuno-deficiency.

Each child receives 5 doses (Oct-Feb) 15mg/kg of pavilizumab

Page 4: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Historical Background

Prior to the centralised clinic babies were receiving individual home visits by a CCN per dose or attending an outpatient facility

Implications: Time Cost Inability to vial share

In order to refine service delivery decided to pilot a centralised CCN led clinic

Page 5: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Working Party

Working party set up in March 2006: Lead CCN Paediatric Pharmacist Named Neonatologist Named Paediatrician

Overall aim to not only to minimise waste and cost but to increase amount of treated children

Page 6: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

The clinic

One clinic a month (initially for 10 children)Central location with parkingAllocated appointments90 minute clinic ran by two nursesVial sharingIntegrated care pathwayPatient held records

Page 7: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Cost Analysis

YearChildren Treated

Total Drug Expenditure

(Doses given) Community

Ward Attender Inpatient

Average cost per

dose

2004/05 6 21, 484

(23)

16 5 2 £934

2005/06 10 36,226

(37)

13 17 7 £979

2006/07 16 32,080

(57)

47 0 10 £563

75 Nursing hours saved

Page 8: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Evaluation

100% attendance throughout seasonParent satisfaction questionnaire Variance trackingNo children were admitted to hospitalEffective social support for families

Page 9: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Season 2007/08

50 % increase in children100 % attendanceSuffolk PCT bought into the clinic for one

patient.

Page 10: Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008

Conclusion

Nurse led services rapidly re shaping nursing services

Local CCNT provision variesCommunication between primary and

secondary care paramount